ReviewJournal of clinical medicine2021
Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Peptides in the Diagnosis and Treatment of Pancreatic Cancer and Other Pancreatic Diseases from Basic Research to Clinical Translation.Drug design, development and therapy · 2026Review
- Prognostic value of interim [European radiology · 2025Article
- Radiopharmaceutical formulation and preliminary clinical dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy.Precision radiation oncology · 2024Review
- Characteristics, therapy, and outcome of rare functioning pancreatic neuroendocrine neoplasms.Scientific reports · 2024Article
- Optimized Production ofNuclear medicine and molecular imaging · 2024Article
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.Journal of medicinal chemistry · 2024Review
- Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.Oncoimmunology · 2024Article
- Predicting the Response of Patients Treated withJournal of medical signals and sensors · 2024Article
- Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report.Experimental and therapeutic medicine · 2023Article
- Article
- Recombinant αBiomolecules · 2023Article
- Preclinical Evaluation of [Molecules (Basel, Switzerland) · 2023Article
- Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases.Journal of clinical medicine · 2023Review
- Correlations between [Cancers · 2023Article
- Evaluating the Presence of a Stage IV Low-Grade Well-Differentiated Neuroendocrine Tumor of the Ileocecum: A Case Report with Evaluation of Staging Protocol of Neuroendocrine Tumors and Treatment Options Based on Current Available Evidence.Case reports in surgery · 2023Article
- The role of serotonin inhibition within the treatment of carcinoid syndrome.Endocrine oncology (Bristol, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.